Inside Startup Investing with Chris Lustrino

Author: Kingscrowd, Sam Fiske

Join Chris Lustrino as he talks to startup founders, angel investors, fund managers, investing platform executives, and more about the online private markets. Inside Startup Investing gives listeners the inside scoop on alternative investing such as startups from an investor and founder perspectives.
Be a guest on this podcast

Language: en-us

Genres: Business, Investing, Technology

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

FDA Progress + Manufacturing Scale: Inside Pirouette Pharma's Latest Round
Episode 165
Wednesday, 25 February, 2026

Pirouette Pharma CEO Conor Cullinane returns to Inside Startup Investing to share the company’s progress since its last Wefunder raise—spanning FDA engagement, IND planning, and major steps toward scalable manufacturing. Pirouette is building a disc-shaped, push-button delivery system for injectable medications—aiming to turn the “violent, error-prone” experience of legacy auto-injectors into something closer to the Staples Easy Button: push once, and the device handles the rest. Chris and Conor discuss why intimidation and usability are major barriers in today’s injection landscape, how Pirouette is approaching OTC naloxone via a combination-product regulatory pathway, what a pharmacokinetic study looks like, and why Pirouette is investing in manufacturing capacity to support both commercialization and pharma partnerships. Chapters 00:44 What Pirouette is building 03:42 Progress since last raise 06:26 FDA pathway explained 09:08 PK study + size/cost/timeline 13:07 Partnerships vs. standalone commercialization 16:15 Revenue timing + adoption expectations 20:12 Manufacturing scale plan 23:34 Founder “why” 26:07 Investor close